Prognosis of patients with primary melanoma Stage I and II according to American Joint Committee on Cancer version 8 validated in two independent cohorts: implications for adjuvant treatment
Eigentler, T. K.
Zouboulis, C. C.
Ascierto, P. A.
Eggermont, A. M. M.
Grob, J. J.
Sekulovic, L. K.
Long, G. V.
Luke, J. J.
Kirkwood, J. M.
Lorigan, Paul C
AffiliationDepartment of Dermatology, Center for Dermatooncology, Eberhard Karls University of Tübingen, Tübingen, Germany
MetadataShow full item record
AbstractPurpose: The first randomized trial of adjuvant treatment with checkpoint inhibitor in stage II melanoma reported a significant reduction in risk of tumor recurrence. This study evaluates two independent data sets to further document survival probabilities for patients with primary stage I and II melanoma. Patients and methods: The Central Malignant Melanoma Registry (CMMR) in Germany evaluated 17,544 patients with a primary diagnosis of stage I and II melanoma from 2000 to 2015. The exploratory cohort consisted of 6,725 patients from the Center for Dermato-Oncology at the University of Tübingen, and the confirmatory cohort consisted of 10,819 patients from 11 other German centers. Survival outcomes were compared with published American Joint Committee on Cancer version 8 (AJCCv8) stage I and II survival data. Results: For the two CMMR cohorts in stage IA compared with the AJCCv8 cohort, melanoma-specific survival rates at 10 years were 95.1%-95.6% versus 98%; 89.7%-90.9% versus 94% in stage IB; 80.7%-83.1% versus 88% in stage IIA; 72.0%-79.9% versus 82% in stage IIB; and 57.6%-64.7% versus 75% in stage IIC, respectively. Recurrence rates were approximately twice as high as melanoma-specific mortality rates in stages IA-IIA. Conclusion: The melanoma-specific survival rates in the two CMMR cohorts across stages I and II are less favorable than published in AJCCv8. This has important implications for the consideration of adjuvant treatment in this population.
CitationGarbe C, Keim U, Amaral T, Berking C, Eigentler TK, Flatz L, et al. Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022.
JournalJournal of Clinical Oncology
- Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts.
- Authors: Garbe C, Keim U, Suciu S, Amaral T, Eigentler TK, Gesierich A, Hauschild A, Heinzerling L, Kiecker F, Schadendorf D, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zouboulis CC, Keilholz U, Testori A, Martus P, Leiter U, Eggermont AMM, German Central Malignant Melanoma Registry and the European Organisation for Research and Treatment of Cancer.
- Issue date: 2020 Aug 1
- Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system.
- Authors: Fujisawa Y, Yoshikawa S, Minagawa A, Takenouchi T, Yokota K, Uchi H, Noma N, Nakamura Y, Asai J, Kato J, Fujiwara S, Fukushima S, Uehara J, Hoashi T, Kaji T, Fujimura T, Namikawa K, Yoshioka M, Murata N, Ogata D, Matsuyama K, Hatta N, Shibayama Y, Fujiyama T, Ishikawa M, Yamada D, Kishi A, Nakamura Y, Shimiauchi T, Fujii K, Fujimoto M, Ihn H, Katoh N
- Issue date: 2019 May
- Novel adjuvant options for cutaneous melanoma.
- Authors: Dimitriou F, Long GV, Menzies AM
- Issue date: 2021 Jul
- Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma.
- Authors: Kanaki T, Stang A, Gutzmer R, Zimmer L, Chorti E, Sucker A, Ugurel S, Hadaschik E, Gräger NS, Satzger I, Schadendorf D, Livingstone E
- Issue date: 2019 Sep
- Surveillance strategies in the follow-up of melanoma patients: too much or not enough?
- Authors: Kurtz J, Beasley GM, Agnese D, Kendra K, Olencki TE, Terando A, Howard JH
- Issue date: 2017 Jun 15